NSEGeneral Updates7 Aug 2026 · 7 Aug 2026, 10:59 pm
General Updates
Dr. Reddy's Laboratories Limited · DRREDDY
✦ AI SummaryRegulatory
Dr. Reddy's Laboratories Limited has terminated its agreement with Novartis India Limited due to a change in controlling shareholding. The agreement was for the distribution and promotion of select brands in India. The company will continue to commercialize the brands until September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
Attachments (1)
📄pdf
Download →
DRREDDY_07082026225902_SE_intimation_070826_signed.pdf
View document text
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com
August 7, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015
This is to inform you that the Company has terminated the agreement dated February 11, 2022, with
Novartis India Limited (NIL) with respect to the distribution and promotion of select brands in India. This
termination follows a change in the controlling shareholding of NIL. The Company will continue to
commercialize the brands covered thereunder until September 30, 2026.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR